Top

Published in:

Open Access 01-12-2022 | Artificial Intelligence | Review

Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics

Authors: Ajaz A. Bhat, Sabah Nisar, Soumi Mukherjee, Nirmalya Saha, Nageswari Yarravarapu, Saife N. Lone, Tariq Masoodi, Ravi Chauhan, Selma Maacha, Puneet Bagga, Punita Dhawan, Ammira Al-Shabeeb Akil, Wael El-Rifai, Shahab Uddin, Ravinder Reddy, Mayank Singh, Muzafar A. Macha, Mohammad Haris

Published in: Journal of Translational Medicine | Issue 1/2022

Abstract

Gene editing has great potential in treating diseases caused by well-characterized molecular alterations. The introduction of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)–based gene-editing tools has substantially improved the precision and efficiency of gene editing. The CRISPR/Cas9 system offers several advantages over the existing gene-editing approaches, such as its ability to target practically any genomic sequence, enabling the rapid development and deployment of novel CRISPR-mediated knock-out/knock-in methods. CRISPR/Cas9 has been widely used to develop cancer models, validate essential genes as druggable targets, study drug-resistance mechanisms, explore gene non-coding areas, and develop biomarkers. CRISPR gene editing can create more-effective chimeric antigen receptor (CAR)-T cells that are durable, cost-effective, and more readily available. However, further research is needed to define the CRISPR/Cas9 system’s pros and cons, establish best practices, and determine social and ethical implications. This review summarizes recent CRISPR/Cas9 developments, particularly in cancer research and immunotherapy, and the potential of CRISPR/Cas9-based screening in developing cancer precision medicine and engineering models for targeted cancer therapy, highlighting the existing challenges and future directions. Lastly, we highlight the role of artificial intelligence in refining the CRISPR system's on-target and off-target effects, a critical factor for the broader application in cancer therapeutics.

Roberts RJ, Murray K. Restriction Endonuclease. CRC Crit Rev Biochem. 1976;4:123–64. https://doi.org/10.3109/10409237609105456.CrossRefPubMed

Mao Z, Bozzella M, Seluanov A, Gorbunova V. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair. 2008;7:1765–71. https://doi.org/10.1016/j.dnarep.2008.06.018.CrossRefPubMedPubMedCentral

Bak RO, Gomez-Ospina N, Porteus MH. Gene editing on center stage. Trends Genet. 2018;34:600–11. https://doi.org/10.1016/j.tig.2018.05.004.CrossRefPubMed

Bailey MH, et al. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020;11:4748. https://doi.org/10.1038/s41467-020-18151-y.CrossRefPubMedPubMedCentral

Shen P, et al. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics. Oncogene. 2018;37:3039–44. https://doi.org/10.1038/s41388-018-0192-5.CrossRefPubMed

Pon JR, Marra MA. Driver and passenger mutations in cancer. Annu Rev Pathol. 2015;10:25–50. https://doi.org/10.1146/annurev-pathol-012414-040312.CrossRefPubMed

Zhang H, et al. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer. 2021;20:126. https://doi.org/10.1186/s12943-021-01431-6.CrossRefPubMedPubMedCentral

Neggers JE, et al. enAsCas12a enables CRISPR-directed evolution to screen for functional drug resistance mutations in sequences inaccessible to SpCas9. Mol Ther. 2021;29:208–24. https://doi.org/10.1016/j.ymthe.2020.09.025.CrossRefPubMed

Neggers JE, et al. Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes. Nat Commun. 2018;9:502. https://doi.org/10.1038/s41467-017-02349-8.CrossRefPubMedPubMedCentral

10.

Neggers JE, et al. Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing. Chem Biol. 2015;22:107–16. https://doi.org/10.1016/j.chembiol.2014.11.015.CrossRefPubMed

11.

Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987;169:5429–33. https://doi.org/10.1128/jb.169.12.5429-5433.1987.CrossRefPubMedPubMedCentral

12.

Jansen R, Embden JD, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002;43:1565–75. https://doi.org/10.1046/j.1365-2958.2002.02839.x.CrossRefPubMed

13.

Mojica FJ, Díez-Villaseñor C, García-Martínez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol. 2005;60:174–82. https://doi.org/10.1007/s00239-004-0046-3.CrossRefPubMed

14.

Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology. 2005;151:2551–61. https://doi.org/10.1099/mic.0.28048-0.CrossRefPubMed

15.

Pourcel C, Salvignol G, Vergnaud G. CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology. 2005;151:653–63. https://doi.org/10.1099/mic.0.27437-0.CrossRefPubMed

16.

Barrangou R, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315:1709–12. https://doi.org/10.1126/science.1138140.CrossRefPubMed

17.

Deltcheva E, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. 2011;471:602–7. https://doi.org/10.1038/nature09886.CrossRefPubMedPubMedCentral

18.

Deveau H, et al. Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J Bacteriol. 2008;190:1390–400. https://doi.org/10.1128/jb.01412-07.CrossRefPubMed

19.

Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A. 2012;109:E2579-2586. https://doi.org/10.1073/pnas.1208507109.CrossRefPubMedPubMedCentral

20.

Jinek M, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–21. https://doi.org/10.1126/science.1225829.CrossRefPubMedPubMedCentral

21.

Sapranauskas R, et al. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res. 2011;39:9275–82. https://doi.org/10.1093/nar/gkr606.CrossRefPubMedPubMedCentral

22.

Jinek M, et al. RNA-programmed genome editing in human cells. Elife. 2013;2:e00471. https://doi.org/10.7554/eLife.00471.CrossRefPubMedPubMedCentral

23.

Mali P, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823–6. https://doi.org/10.1126/science.1232033.CrossRefPubMedPubMedCentral

24.

Cong L, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819–23. https://doi.org/10.1126/science.1231143.CrossRefPubMedPubMedCentral

25.

Qi LS, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152:1173–83. https://doi.org/10.1016/j.cell.2013.02.022.CrossRefPubMedPubMedCentral

26.

Maeder ML, et al. CRISPR RNA-guided activation of endogenous human genes. Nat Methods. 2013;10:977–9. https://doi.org/10.1038/nmeth.2598.CrossRefPubMedPubMedCentral

27.

Shalem O, et al. Genome-scale CRISPR-Cas9 knock-out screening in human cells. Science. 2014;343:84–7. https://doi.org/10.1126/science.1247005.CrossRefPubMed

28.

Erb MA, et al. Transcription control by the ENL YEATS domain in acute leukaemia. Nature. 2017;543:270–4. https://doi.org/10.1038/nature21688.CrossRefPubMedPubMedCentral

29.

Gilbert LA, et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell. 2014;159:647–61. https://doi.org/10.1016/j.cell.2014.09.029.CrossRefPubMedPubMedCentral

30.

Du D, et al. Genetic interaction mapping in mammalian cells using CRISPR interference. Nat Methods. 2017;14:577–80. https://doi.org/10.1038/nmeth.4286.CrossRefPubMedPubMedCentral

31.

Chow RD, et al. In vivo profiling of metastatic double knock-outs through CRISPR-Cpf1 screens. Nat Methods. 2019;16:405–8. https://doi.org/10.1038/s41592-019-0371-5.CrossRefPubMedPubMedCentral

32.

Chen S, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160:1246–60. https://doi.org/10.1016/j.cell.2015.02.038.CrossRefPubMedPubMedCentral

33.

Chow RD, Chen S. Cancer CRISPR screens in vivo. Trends Cancer. 2018;4:349–58. https://doi.org/10.1016/j.trecan.2018.03.002.CrossRefPubMedPubMedCentral

34.

Wang G, et al. Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening. Sci Adv. 2018;4:eaao5508. https://doi.org/10.1126/sciadv.aao5508.CrossRefPubMedPubMedCentral

35.

Dixit A, et al. Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. Cell. 2016;167:1853-1866.e1817. https://doi.org/10.1016/j.cell.2016.11.038.CrossRefPubMedPubMedCentral

36.

Jaitin DA, et al. Dissecting immune circuits by linking CRISPR-pooled screens with single-Cell RNA-seq. Cell. 2016;167:1883-1896.e1815. https://doi.org/10.1016/j.cell.2016.11.039.CrossRefPubMed

37.

Datlinger P, et al. Pooled CRISPR screening with single-cell transcriptome readout. Nat Methods. 2017;14:297–301. https://doi.org/10.1038/nmeth.4177.CrossRefPubMedPubMedCentral

38.

Stoeckius M, et al. Simultaneous epitope and transcriptome measurement in single cells. Nat Methods. 2017;14:865–8. https://doi.org/10.1038/nmeth.4380.CrossRefPubMedPubMedCentral

39.

Frangieh CJ, et al. Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nat Genet. 2021;53:332–41. https://doi.org/10.1038/s41588-021-00779-1.CrossRefPubMedPubMedCentral

40.

Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020;38:824–44. https://doi.org/10.1038/s41587-020-0561-9.CrossRefPubMed

41.

Annunziato S, et al. In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer. Embo j. 2020;39:e102169. https://doi.org/10.15252/embj.2019102169.CrossRefPubMedPubMedCentral

42.

Hanna RE, et al. Massively parallel assessment of human variants with base editor screens. Cell. 2021;184:1064-1080.e1020. https://doi.org/10.1016/j.cell.2021.01.012.CrossRefPubMed

43.

Cuella-Martin R, et al. Functional interrogation of DNA damage response variants with base editing screens. Cell. 2021;184:1081-1097.e1019. https://doi.org/10.1016/j.cell.2021.01.041.CrossRefPubMedPubMedCentral

44.

Winters AC, Bernt KM. MLL-rearranged leukemias-an update on science and clinical approaches. Front Pediatr. 2017;5:4. https://doi.org/10.3389/fped.2017.00004.CrossRefPubMedPubMedCentral

45.

Lu B, et al. A transcription factor addiction in leukemia imposed by the MLL promoter sequence. Cancer Cell. 2018;34:970-981.e978. https://doi.org/10.1016/j.ccell.2018.10.015.CrossRefPubMedPubMedCentral

46.

Au YZ, et al. KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements. Leukemia. 2021;35:1012–22. https://doi.org/10.1038/s41375-020-1001-z.CrossRefPubMed

47.

Dai M, et al. In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy. Nat Commun. 2021;12:3055. https://doi.org/10.1038/s41467-021-23316-4.CrossRefPubMedPubMedCentral

48.

Liang J, et al. Genome-wide CRISPR-Cas9 screen reveals selective vulnerability of ATRX-mutant cancers to WEE1 inhibition. Cancer Res. 2020;80:510–23. https://doi.org/10.1158/0008-5472.Can-18-3374.CrossRefPubMed

49.

Li K, Luo H, Huang L, Luo H, Zhu X. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int. 2020;20:16. https://doi.org/10.1186/s12935-019-1091-8.CrossRefPubMedPubMedCentral

50.

Chan EM, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019;568:551–6. https://doi.org/10.1038/s41586-019-1102-x.CrossRefPubMedPubMedCentral

51.

Shu S, et al. Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer. Mol Cell. 2020;78:1096-1113.e1098. https://doi.org/10.1016/j.molcel.2020.04.027.CrossRefPubMedPubMedCentral

52.

Mo Z, et al. Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen. Blood Adv. 2021;5:2027–39. https://doi.org/10.1182/bloodadvances.2020003431.CrossRefPubMedPubMedCentral

53.

Chen J, et al. Genome-scale CRISPR-Cas9 transcriptional activation screening in metformin resistance related gene of prostate cancer. Front Cell Dev Biol. 2020;8:616332. https://doi.org/10.3389/fcell.2020.616332.CrossRefPubMed

54.

Thomas GB, et al. Antimicrobial activity of amniotic fluid against Chlamydia trachomatis, Mycoplasma hominis, and Ureaplasma urealyticum. Am J Obstet Gynecol. 1988;158:16–22. https://doi.org/10.1016/0002-9378(88)90767-3.CrossRefPubMed

55.

Dai X, et al. Innovative precision gene-editing tools in personalized cancer medicine. Adv Sci. 2020;7:1902552. https://doi.org/10.1002/advs.201902552.CrossRef

56.

Hai T, Teng F, Guo R, Li W, Zhou Q. One-step generation of knock-out pigs by zygote injection of CRISPR/Cas system. Cell Res. 2014;24:372–5. https://doi.org/10.1038/cr.2014.11.CrossRefPubMedPubMedCentral

57.

Friedland AE, et al. Heritable genome editing in C elegans via a CRISPR-Cas9 system. Nat Methods. 2013;10:741–3. https://doi.org/10.1038/nmeth.2532.CrossRefPubMedPubMedCentral

58.

Niu Y, et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell. 2014;156:836–43. https://doi.org/10.1016/j.cell.2014.01.027.CrossRefPubMed

59.

Hwang WY, et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 2013;31:227–9. https://doi.org/10.1038/nbt.2501.CrossRefPubMedPubMedCentral

60.

Brunet E, Jasin M. Induction of chromosomal translocations with CRISPR-Cas9 and other nucleases: understanding the repair mechanisms that give rise to translocations. Adv Exp Med Biol. 2018;1044:15–25. https://doi.org/10.1007/978-981-13-0593-1_2.CrossRefPubMedPubMedCentral

61.

Sasaki T, Rodig SJ, Chirieac LR, Jänne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010;46:1773–80. https://doi.org/10.1016/j.ejca.2010.04.002.CrossRefPubMedPubMedCentral

62.

Reimer J, et al. CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo. Haematologica. 2017;102:1558–66. https://doi.org/10.3324/haematol.2017.164046.CrossRefPubMedPubMedCentral

63.

Jeong J, et al. High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells. Blood Adv. 2019;3:2825–35. https://doi.org/10.1182/bloodadvances.2019000450.CrossRefPubMedPubMedCentral

64.

Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science. 2019;364:952–5. https://doi.org/10.1126/science.aaw6985.CrossRefPubMed

65.

Zhang S, et al. Genetically defined, syngeneic organoid platform for developing combination therapies for ovarian cancer. Cancer Discov. 2021;11:362–83. https://doi.org/10.1158/2159-8290.Cd-20-0455.CrossRefPubMed

66.

Dekkers JF, et al. Modeling breast cancer using crispr-cas9-mediated engineering of human breast organoids. J Natl Cancer Inst. 2020;112:540–4. https://doi.org/10.1093/jnci/djz196.CrossRefPubMed

67.

Murakami K, et al. A genome-scale CRISPR screen reveals factors regulating Wnt-dependent renewal of mouse gastric epithelial cells. Proc Natl Acad Sci USA. 2021. https://doi.org/10.1073/pnas.2016806118.CrossRefPubMedPubMedCentral

68.

Kirkwood JM, et al. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62:309–35. https://doi.org/10.3322/caac.20132.CrossRefPubMedPubMedCentral

69.

Huang PW, Chang JW. Immune checkpoint inhibitors win the 2018 nobel prize. Biomed J. 2019;42:299–306. https://doi.org/10.1016/j.bj.2019.09.002.CrossRefPubMedPubMedCentral

70.

Xia AL, et al. Applications and advances of CRISPR-Cas9 in cancer immunotherapy. J Med Genet. 2019;56:4–9. https://doi.org/10.1136/jmedgenet-2018-105422.CrossRefPubMed

71.

Ledford H. CRISPR treatment inserted directly into the body for first time. Nature. 2020;579:185. https://doi.org/10.1038/d41586-020-00655-8.CrossRefPubMed

72.

Cyranoski D. Chinese scientists to pioneer first human CRISPR trial. Nature. 2016;535:476–7. https://doi.org/10.1038/nature.2016.20302.CrossRefPubMed

73.

Liu Q. World-first phase I clinical trial for CRISPR-Cas9 PD-1-edited T-cells in advanced nonsmall cell lung cancer. Glob Med Genet. 2020;7:73–4. https://doi.org/10.1055/s-0040-1721451.CrossRefPubMedPubMedCentral

74.

Lu Y, et al. Publisher correction: safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med. 2020;26:1149. https://doi.org/10.1038/s41591-020-0973-6.CrossRefPubMed

75.

He S. The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer. Signal Transduct Target Ther. 2020;5:168. https://doi.org/10.1038/s41392-020-00283-8.CrossRefPubMedPubMedCentral

76.

Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69. https://doi.org/10.1038/s41408-021-00459-7.CrossRefPubMedPubMedCentral

77.

Baylis F, McLeod M. First-in-human phase 1 CRISPR gene editing cancer trials: are we ready? Curr Gene Ther. 2017;17:309–19. https://doi.org/10.2174/1566523217666171121165935.CrossRefPubMedPubMedCentral

78.

Stadtmauer EA, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020. https://doi.org/10.1126/science.aba7365.CrossRefPubMed

79.

Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14:73. https://doi.org/10.1186/s13045-021-01083-5.CrossRefPubMedPubMedCentral

80.

Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin Immunol. 2017;31:37–54. https://doi.org/10.1016/j.smim.2017.07.009.CrossRefPubMed

81.

Basar R, Daher M, Rezvani K. Next-generation cell therapies: the emerging role of CAR-NK cells. Hematology Am Soc Hematol Educ Program. 2020;570–578:2020. https://doi.org/10.1182/hematology.2020002547.CrossRef

82.

Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra138. https://doi.org/10.1126/scitranslmed.3005930.CrossRef

83.

Kalos M, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73. https://doi.org/10.1126/scitranslmed.3002842.CrossRefPubMedPubMedCentral

84.

Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–87. https://doi.org/10.1038/nrc.2016.36.CrossRefPubMedPubMedCentral

85.

Khalaf K, et al. CRISPR/Cas9 in cancer immunotherapy: animal models and human clinical trials. Genes. 2020. https://doi.org/10.3390/genes11080921.CrossRefPubMedPubMedCentral

86.

Razzouk S. CRISPR-Cas9: a cornerstone for the evolution of precision medicine. Ann Hum Genet. 2018;82:331–57. https://doi.org/10.1111/ahg.12271.CrossRefPubMed

87.

Naeem M, Majeed S, Hoque MZ, Ahmad I. Latest developed strategies to minimize the Off-target effects in CRISPR-Cas-mediated genome editing. Cells. 2020. https://doi.org/10.3390/cells9071608.CrossRefPubMedPubMedCentral

88.

Ardhanareeswaran K, Mariani J, Coppola G, Abyzov A, Vaccarino FM. Human induced pluripotent stem cells for modelling neurodevelopmental disorders. Nat Rev Neurol. 2017;13:265–78. https://doi.org/10.1038/nrneurol.2017.45.CrossRefPubMedPubMedCentral

89.

Liao HK, et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun. 2015;6:6413. https://doi.org/10.1038/ncomms7413.CrossRefPubMed

90.

De Masi C, Spitalieri P, Murdocca M, Novelli G, Sangiuolo F. Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery. Hum Genomics. 2020;14:25. https://doi.org/10.1186/s40246-020-00276-2.CrossRefPubMedPubMedCentral

91.

Soldner F, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell. 2011;146:318–31. https://doi.org/10.1016/j.cell.2011.06.019.CrossRefPubMedPubMedCentral

92.

Gupta RM, Musunuru K. Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest. 2014;124:4154–61. https://doi.org/10.1172/JCI72992.CrossRefPubMedPubMedCentral

93.

Maino E, et al. Targeted genome editing in vivo corrects a Dmd duplication restoring wild-type dystrophin expression. EMBO Mol Med. 2021;13:e13228. https://doi.org/10.15252/emmm.202013228.CrossRefPubMedPubMedCentral

94.

Qin W, Wang H. Delivery of CRISPR-Cas9 into mouse zygotes by electroporation. Methods Mol Biol. 1874;179–190:2019. https://doi.org/10.1007/978-1-4939-8831-0_10.CrossRef

95.

Toda E, Okamoto T. CRISPR/Cas9-based genome editing using Rice Zygotes. Curr Protoc Plant Biol. 2020;5:e20111. https://doi.org/10.1002/cppb.20111.CrossRefPubMed

96.

Alanis-Lobato G, et al. Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos. Proc Natl Acad Sci. 2021;118:e2004832117. https://doi.org/10.1073/pnas.2004832117.CrossRefPubMedPubMedCentral

97.

Zuccaro MV, et al. Allele-specific chromosome removal after Cas9 cleavage in human embryos. Cell. 2020;183:1650-1664.e1615. https://doi.org/10.1016/j.cell.2020.10.025.CrossRefPubMed

98.

Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature. 2016;539:479–479. https://doi.org/10.1038/nature.2016.20988.CrossRefPubMed

99.

Ganbaatar U, Liu C. CRISPR-based COVID-19 testing: toward next-generation point-of-care diagnostics. Front Cell Infect Microbiol. 2021. https://doi.org/10.3389/fcimb.2021.663949.CrossRefPubMedPubMedCentral

100.

Abudayyeh OO, et al. RNA targeting with CRISPR–Cas13. Nature. 2017;550:280–4. https://doi.org/10.1038/nature24049.CrossRefPubMedPubMedCentral

101.

Carter LJ, et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci. 2020;6:591–605. https://doi.org/10.1021/acscentsci.0c00501.CrossRefPubMedPubMedCentral

102.

Konstantakos V, Nentidis A, Krithara A, Paliouras G. CRISPR–Cas9 gRNA efficiency prediction: an overview of predictive tools and the role of deep learning. Nucleic Acids Res. 2022;50:3616–37. https://doi.org/10.1093/nar/gkac192.CrossRefPubMedPubMedCentral

103.

Chuai G-H, Wang Q-L, Liu Q. In silico meets in vivo: towards computational CRISPR-based sgRNA design. Trends Biotechnol. 2017;35:12–21.CrossRefPubMed

104.

Henry VJ, Bandrowski AE, Pepin A-S, Gonzalez BJ, Desfeux A. OMICtools: an informative directory for multi-omic data analysis. Database. 2014. https://doi.org/10.1093/database/bau069.CrossRefPubMedPubMedCentral

105.

Xu H, et al. Sequence determinants of improved CRISPR sgRNA design. Genome Res. 2015;25:1147–57. https://doi.org/10.1101/gr.191452.115.CrossRefPubMedPubMedCentral

106.

Moreno-Mateos MA, et al. CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. Nat Methods. 2015;12:982–8. https://doi.org/10.1038/nmeth.3543.CrossRefPubMedPubMedCentral

107.

Labuhn M, et al. Refined sgRNA efficacy prediction improves large-and small-scale CRISPR–Cas9 applications. Nucleic Acids Res. 2018;46:1375–85.CrossRefPubMed

108.

Doench JG, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34:184–91. https://doi.org/10.1038/nbt.3437.CrossRefPubMedPubMedCentral

109.

Wilson LOW, Reti D, O’Brien AR, Dunne RA, Bauer DC. High activity target-site identification using phenotypic independent CRISPR-cas9 core functionality. Crispr J. 2018;1:182–90. https://doi.org/10.1089/crispr.2017.0021.CrossRefPubMed

110.

Doench JG, et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol. 2014;32:1262–7. https://doi.org/10.1038/nbt.3026.CrossRefPubMedPubMedCentral

111.

Wong N, Liu W, Wang X. WU-CRISPR: characteristics of functional guide RNAs for the CRISPR/Cas9 system. Genome Biol. 2015;16:218. https://doi.org/10.1186/s13059-015-0784-0.CrossRefPubMedPubMedCentral

112.

Chari R, Mali P, Moosburner M, Church GM. Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach. Nat Methods. 2015;12:823–6. https://doi.org/10.1038/nmeth.3473.CrossRefPubMedPubMedCentral

113.

Chari R, Yeo NC, Chavez A, Church GM. sgRNA Scorer 20: a species-independent model to predict CRISPR/Cas9 activity. ACS Synth Biol. 2017;6:902–4.CrossRefPubMedPubMedCentral

114.

Peng H, Zheng Y, Blumenstein M, Tao D, Li J. CRISPR/Cas9 cleavage efficiency regression through boosting algorithms and Markov sequence profiling. Bioinformatics. 2018;34:3069–77. https://doi.org/10.1093/bioinformatics/bty298.CrossRefPubMed

115.

Hiranniramol K, Chen Y, Liu W, Wang X. Generalizable sgRNA design for improved CRISPR/Cas9 editing efficiency. Bioinformatics. 2020;36:2684–9. https://doi.org/10.1093/bioinformatics/btaa041.CrossRefPubMedPubMedCentral

116.

Tsai SQ, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015;33:187–97.CrossRefPubMed

117.

Frock RL, et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol. 2015;33:179–86.CrossRefPubMed

118.

Wang X, et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol. 2015;33:175–8.CrossRefPubMed

119.

Wilson LO, Reti D, O’Brien AR, Dunne RA, Bauer DC. High activity target-site identification using phenotypic independent CRISPR-Cas9 core functionality. The CRISPR Journal. 2018;1:182–90.CrossRefPubMed

120.

Chuai G, et al. DeepCRISPR: optimized CRISPR guide RNA design by deep learning. Genome Biol. 2018;19:1–18.CrossRef

121.

Xue L, Tang B, Chen W, Luo J. Prediction of CRISPR sgRNA activity using a deep convolutional neural network. J Chem Inf Model. 2018;59:615–24.CrossRefPubMed

122.

Wong N, Liu W, Wang X. WU-CRISPR: characteristics of functional guide RNAs for the CRISPR/Cas9 system. Genome Biol. 2015;16:1–8.CrossRef

123.

Rahman MK, Rahman MS. CRISPRpred: a flexible and efficient tool for sgRNAs on-target activity prediction in CRISPR/Cas9 systems. PLoS ONE. 2017;12:e0181943.CrossRefPubMedPubMedCentral

124.

Wang D, et al. Optimized CRISPR guide RNA design for two high-fidelity Cas9 variants by deep learning. Nat Commun. 2019;10:4284. https://doi.org/10.1038/s41467-019-12281-8.CrossRefPubMedPubMedCentral

125.

Zhang G, Dai Z, Dai X. A novel hybrid CNN-SVR for CRISPR/Cas9 guide RNA activity prediction. Front Genet. 2019;10:1303. https://doi.org/10.3389/fgene.2019.01303.CrossRefPubMed

126.

Zhang G, Dai Z, Dai X. C-RNNCrispr: Prediction of CRISPR/Cas9 sgRNA activity using convolutional and recurrent neural networks. Comput Struct Biotechnol J. 2020;18:344–54. https://doi.org/10.1016/j.csbj.2020.01.013.CrossRefPubMedPubMedCentral

127.

Gratz SJ, et al. Highly specific and efficient CRISPR/Cas9-catalyzed homology-directed repair in Drosophila. Genetics. 2014;196:961–71.CrossRefPubMedPubMedCentral

128.

McKenna A, Shendure J. FlashFry: a fast and flexible tool for large-scale CRISPR target design. BMC Biol. 2018;16:1–6.CrossRef

129.

Listgarten J, et al. Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs. Nature Biomed Eng. 2018;2:38–47.CrossRef

130.

Haeussler M, et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 2016;17:1–12.CrossRef

131.

Lin J, Wong K-C. Off-target predictions in CRISPR-Cas9 gene editing using deep learning. Bioinformatics. 2018;34:i656–63.CrossRefPubMedPubMedCentral

132.

Peng H, Zheng Y, Zhao Z, Liu T, Li J. Recognition of CRISPR/Cas9 off-target sites through ensemble learning of uneven mismatch distributions. Bioinformatics. 2018;34:i757–65.CrossRefPubMed

133.

Kleinstiver BP, et al. High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529:490–5.CrossRefPubMedPubMedCentral

134.

Katti A, Diaz BJ, Caragine CM, Sanjana NE, Dow LE. CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022;22:259–79. https://doi.org/10.1038/s41568-022-00441-w.CrossRefPubMed

135.

Wang G, et al. Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nat Immunol. 2019;20:1494–505. https://doi.org/10.1038/s41590-019-0500-4.CrossRefPubMedPubMedCentral

136.

Blanas A, et al. Transcriptional activation of fucosyltransferase (FUT) genes using the CRISPR-dCas9-VPR technology reveals potent N-glycome alterations in colorectal cancer cells. Glycobiology. 2019;29:137–50. https://doi.org/10.1093/glycob/cwy096.CrossRefPubMed

137.

Hill ZB, Martinko AJ, Nguyen DP, Wells JA. Human antibody-based chemically induced dimerizers for cell therapeutic applications. Nat Chem Biol. 2018;14:112–7. https://doi.org/10.1038/nchembio.2529.CrossRefPubMed

138.

Jost M, et al. Combined CRISPRi/a-based chemical genetic screens reveal that rigosertib is a microtubule-destabilizing agent. Mol Cell. 2017;68:210-223.e216. https://doi.org/10.1016/j.molcel.2017.09.012.CrossRefPubMedPubMedCentral

139.

Ramkumar P, et al. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv. 2020;4:2899–911. https://doi.org/10.1182/bloodadvances.2019001346.CrossRefPubMedPubMedCentral

140.

Liu SJ, et al. CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma. Genome Biol. 2020;21:83. https://doi.org/10.1186/s13059-020-01995-4.CrossRefPubMedPubMedCentral

141.

Yoshida M, et al. Development of an integrated CRISPRi targeting ΔNp63 for treatment of squamous cell carcinoma. Oncotarget. 2018;9:29220–32. https://doi.org/10.18632/oncotarget.25678.CrossRefPubMedPubMedCentral

142.

Ji AL, et al. Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma. Cell. 2020;182:1661–2. https://doi.org/10.1016/j.cell.2020.08.043.CrossRefPubMedPubMedCentral

143.

Pierce SE, Granja JM, Greenleaf WJ. High-throughput single-cell chromatin accessibility CRISPR screens enable unbiased identification of regulatory networks in cancer. Nat Commun. 2021;12:2969. https://doi.org/10.1038/s41467-021-23213-w.CrossRefPubMedPubMedCentral

144.

Einstein JM, et al. Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Mol Cell. 2021;81:3048-3064.e3049. https://doi.org/10.1016/j.molcel.2021.06.014.CrossRefPubMedPubMedCentral

145.

Li X, et al. Programmable base editing of mutated TERT promoter inhibits brain tumour growth. Nat Cell Biol. 2020;22:282–8. https://doi.org/10.1038/s41556-020-0471-6.CrossRefPubMed

146.

Shi X, et al. Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity. J Hematol Oncol. 2019;12:127. https://doi.org/10.1186/s13045-019-0831-5.CrossRefPubMedPubMedCentral

147.

Webber BR, et al. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat Commun. 2019;10:5222. https://doi.org/10.1038/s41467-019-13007-6.CrossRefPubMedPubMedCentral

148.

Roth TL, et al. Pooled knockin targeting for genome engineering of cellular immunotherapies. Cell. 2020;181:728-744.e721. https://doi.org/10.1016/j.cell.2020.03.039.CrossRefPubMedPubMedCentral

149.

Okamoto T, Natsume Y, Yamanaka H, Fukuda M, Yao R. A protocol for efficient CRISPR-Cas9-mediated knock-in in colorectal cancer patient-derived organoids. STAR Protoc. 2021;2:100780. https://doi.org/10.1016/j.xpro.2021.100780.CrossRefPubMedPubMedCentral

150.

Tejero R, et al. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment. EBioMedicine. 2019;42:252–69. https://doi.org/10.1016/j.ebiom.2019.03.064.CrossRefPubMedPubMedCentral

151.

Goto N, et al. Lineage tracing and targeting of IL17RB(+) tuft cell-like human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2019;116:12996–3005. https://doi.org/10.1073/pnas.1900251116.CrossRefPubMedPubMedCentral

152.

Takeda H, et al. CRISPR-Cas9-mediated gene knock-out in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proc Natl Acad Sci USA. 2019;116:15635–44. https://doi.org/10.1073/pnas.1904714116.CrossRefPubMedPubMedCentral

153.

Walton J, et al. CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma. Cancer Res. 2016;76:6118–29. https://doi.org/10.1158/0008-5472.Can-16-1272.CrossRefPubMedPubMedCentral

154.

Wang M, et al. Fibrinogen alpha chain knockout promotes tumor growth and metastasis through integrin-AKT signaling pathway in lung cancer. Mol Cancer Res. 2020;18:943–54. https://doi.org/10.1158/1541-7786.Mcr-19-1033.CrossRefPubMed

155.

Khalil BD, et al. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2022. https://doi.org/10.1084/jem.20210836.CrossRefPubMed

Title: Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics
Authors: Ajaz A. Bhat
Sabah Nisar
Soumi Mukherjee
Nirmalya Saha
Nageswari Yarravarapu
Saife N. Lone
Tariq Masoodi
Ravi Chauhan
Selma Maacha
Puneet Bagga
Punita Dhawan
Ammira Al-Shabeeb Akil
Wael El-Rifai
Shahab Uddin
Ravinder Reddy
Mayank Singh
Muzafar A. Macha
Mohammad Haris
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Artificial Intelligence
Cancer Immunotherapy
Published in: Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-022-03765-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients

Pre-neuromusculoskeletal injury Risk factor Evaluation and Post-neuromusculoskeletal injury Assessment for Return-to-duty/activity Enhancement (PREPARE) in military service members: a prospective, observational study protocol

Transplanted allogeneic cardiac progenitor cells secrete GDF-15 and stimulate an active immune remodeling process in the ischemic myocardium

Low potassium disrupt intestinal barrier and result in bacterial translocation

The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma

New challenges for microRNAs in acute pancreatitis: progress and treatment

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage